Premium
Recommended revisions to American Dental Association guidelines for acceptance of chemotherapeutic products for gingivitis control
Author(s) -
Imrey P. B.,
Chilton N. W.,
Pihlstrom B. L.,
Proskin H. M.,
Kingman A.,
Listgarten M. A.,
Zimmerman S. O.,
Ciancio S. G.,
Cohen M. E.,
D'Agostino R. B.,
Fischman S. L.,
Fleiss J. L.,
Gunsolley J. C.,
Kent R. L.,
Killoy W. J.,
Laster L. L.,
Marks R. G.,
Varma A. O.
Publication year - 1994
Publication title -
journal of periodontal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.31
H-Index - 83
eISSN - 1600-0765
pISSN - 0022-3484
DOI - 10.1111/j.1600-0765.1994.tb01225.x
Subject(s) - gingivitis , association (psychology) , medicine , dentistry , environmental health , psychology , psychotherapist
This paper presents suggested revisions to the American Dental Association's 1985 guidelines for acceptance of anti‐gingivitis chemotherapeutic agents. The areas of study design, choice and quality control of clinical gingivitis measurements, statistical analysis, and minimum strength of effect, are addressed. The revisions articulate certain aspects of study design which were implicit in the 1985 guidelines, clarify language on cross‐over designs and independence of studies, and recommend use of a United States population in at least one trial supporting a product. Separate recording and analysis of a product's effect on gingival bleeding is proposed, and quality control of clinical measurements receives enhanced emphasis. Modestly elaborated statistical reporting guidelines and strengthened approval criteria, based on size of estimated effect as well as statistical significance, are advocated.